Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Phase 2 trial more than likely
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(39)
•••
Comment by RunningofdBullson Aug 12, 2021 9:49am
192 Views
Post# 33691023

RE:RE:Phase 2 trial more than likely

RE:RE:Phase 2 trial more than likely
nozzpack wrote: That is not my reading.
Everything went fine at 75 mg.

These 3 patients may have had several diagnostic outcomes that could be unrelated to dosage in which case their results can be omitted from the trial results .

So, that is a necessary process which might turn out to be of no concern for the 100 mg dose.

That there were no safety concerns in previous trials suggest that these three  are outliers whose response was not dose related..


Stauffer himself said AME results were drug related, more specifically dosage related. Yes, 75 mg was no issue for AME but they need to prove full safety and efficacy with a Phase 2. They'll do 50mg for sure and maybe even 25mg if they're smart. They stated a number of times how surprised they are with the potency of the drug.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities